Skip to main content
IMNM $15.69 -5.54%
IMNM logo
IMNM · Immunome Inc.
Track IMNM — free
$15.69 -0.92 (-5.54%) At close · Nov 20
Market Cap
$1.85B
Shares
118.07M
Volume · Nov 20 1.06M Avg daily vol (3M) 1.35M
All webcasts

Conference · 2026-11-10

Immunome Inc. (IMNM) November 10, 2026 Conference Transcript

Concluded Nov 10, 2026 Audio replay
Nov 10, 2026 25:56 23 turns
Period
2026-11-10
Runtime
25:56
Sources
2 artifacts

Transcript & audio

25:56 Audio
Michael Schmidt Analyst — Guggenheim

Discussion with Clay Segal, CEO of Immunome. My name is Michael Schmidt, Senior Biotech Analyst with Guggenheim, and I'm really looking forward to this. Clay, welcome. Thanks for joining us.

Thanks for inviting me to your conference.

Michael Schmidt Analyst — Guggenheim

So Clay, obviously you have a lot going on at Immunome. You have variegases studied from the FDA, you have an ADC pipeline in the radioligin therapy in the clinic as well. As you think about the next 12 months for the company, what are your key focus areas as you take the company into this next stage?

So, clearly, Vargasostat would come first. We have an action date or PDUFA date from FDA at the end of April in 2027. So, we're excited to get that onto the market. We are well-prepared commercially, well-prepared manufacturing. And working hard at that. Also, over the next 12 months with Varagasystat, we are working really hard with... The European Medicines Agency, we submitted and got validated there, which is sort of like getting filed in the U.S., and they're equivalent. And so we're working hard with the regulators in the U.S. and Europe. We're also doing the requisite, you know, meetings and clinical work we need to do in Japan. And, and also, you know, we're working with potential. We are looking at this as a global product and doing everything we can to get this to patients in need once we get approval. So that is going on. We also have a number of clinical trials that we're pursuing with varagastastat that we'll talk more about in the coming, you know, times to see if we could broaden out our, our labels. So, Vargasistat represents something very important to us in our first commercial product. Okay, and then over the next 12 months, I would say the one other big thing would be putting out a lot of clinical data on our many ADCs and really validating our new technology, which we think is state-of-the-art, one of the best, if not the best, ADC technologies out there, fixing many of the problems that were in ADCs over the last few decades, many of Which I... Propagated. So, I'd like to, we'd like to really do something dramatic and differentiated for patients with ADCs looking into the future. So, you'll hear a lot of clinical data starting with ASH, which is next month.

Michael Schmidt Analyst — Guggenheim

Yeah. On Varigasestad... How is the product going to be positioned in the decimally tumor market? Obviously, there's a similar drug already on the market. What are the key focus areas as you detail that product makes CO2 physicians?

So our product, Farragastastat, outperforms the current product on the market in every way you could look at the product. It has a higher response rate. It is once-a-day dosing. It's very effective on pain relief, as we detailed in our presentation, and there are many different aspects of it. So it's a premier, first-in-class product. So when you look at the incident patients, We think that, you know, our commercial team will be out there talking to doctors about using this as the first choice in the incident population. There's a prevalent population out there which is much larger than the incident population, and the prevalent population is something that not all patients come in for therapy each year. You know, the incident population is about 1,600 in the U.S. each year, about the same in the EMA. When you look at the prevalent population, there's over 30,000 patients with desmoid in the U.S. Now, about 10,000, 11,000 of them come into therapy each year based on medical records, and they're looking for something. And it's usually to combat pain because they have pain, which pain is correlated with tumor growth. And so they want something. And over the years, docs have been giving them things like radiation or off-label drugs like Sutent. And only a few years ago, the very first drug ever approved for desmoid was niragastastat. It gave another opportunity for patients. Our drug, we believe all the data is just so much better. It's such an improved therapeutic agent, largely because it has much better pharmacokinetics. And that's really the underlying reason why this drug is much better. So we think that that is a great opportunity for all the... Incident and prevalent patients. So we're going to go out there and try to do the best we can in representing patients and giving them opportunity to get the best possible outcome they can.

Michael Schmidt Analyst — Guggenheim

Yeah. Any learnings from the Nairo Gassistat launch and that, you know, you could implement or that you could leverage as you implement the launch next year? And talk about how launch ready are you and how much more commercial build is necessary to support the launch next year?

Yeah, you know, what I can say is looking at a distance at what happened with Nyrogastastat, I mean, I do have to say it was a time where, you know, Springworks, there was rumors in the Wall Street Journal they were going to get acquired and then ended up getting acquired months later. And it's hard to launch a drug while you're in the middle of an acquisition. So I'll give them that, that, you know, there are, you know, logistical issues with that. And so, you know, that's one thing. We don't have that. We're, you know, very focused on it. I think another thing is we are very focused on medical affairs and connecting with doctors. And, you know, I've launched many drugs in my career, and medical affairs is critical to having a successful launch. And so we have the best medical affairs team that we can have. A lot of them came from CGen. The leadership came from CGen. So I've known them for a long, long period of time, and they did fantastic work and continue to. So I'm very pleased with our ability to hit the ground running based on medical affairs. As far as the commercial team, our commercial leadership is Rowei Shahar, and he launched two drugs at CGen. He is a superstar commercial guy, and we are very well positioned to go forward with our commercial team. You know, our head of manufacturing, Phil Tsai, also came from CGen, where he literally made every product CGen had, including the small molecule Tukiza, which is, you know, in a sense similar because it's an oral drug to varagastat as well as all our ADCs. So I think we are, while we're a small company and we're only a little more than three years old, we're an extremely experienced company. So I think that launching a drug for us, for most small companies, is, you know, hard. And I remember launching the first drug at CGen, and, you know, you're a little bit like a deer in headlights when you do it. After launching many drugs now, this is, we have a very strong playbook and experienced people. So I feel very confident we're going to get out there and get this medicine around to patients.

Michael Schmidt Analyst — Guggenheim

Okay. How big could Varigazistat be in terms of peak sales potential?

We have not yet given sales guidance and everything. You know, the price of nirogastastat, which is out there, is expensive. And I think it's around $390,000 for a year of therapy. And, you know, on our trial, the average patient was on for 20 months. And so, you know, it is an expensive drug. It's a rare disease drug. And so we have not priced our drug yet, but I'm convinced based on interactions, And we've had with payers that they understand the value that we have here and that the value is higher than Nyrogastastat. So certainly, it's going to be a premium-priced drug. And we haven't come out yet. It's really, for every drug I've ever launched, I've never talked about the price of the drug until after approval. So I think that's bad karma. And I think that also, you know, giving guidance on a drug before approval is also not appropriate yet. But, you know, you look at something where a price is $390,000, like niragastat, so how do you get to a billion-dollar drug? And you could calculate how many patients you need. You know, you need 2,500 patients or 3,000 patients to become a billion-dollar drug. Is that possible with 1,600 new patients that are treated for longer than a year and, you know, 11,000 of the 31,000 patients in the prevalence pool coming in looking for some therapy? Certainly, it's possible to have a really good market. And then you have all Europe and the rest of the world. So we're looking at this as a global drug. And we're not putting limits on it. And I've seen all you and other analysts. You know, and there's a range of what analysts are thinking and so we haven't commented on it yet, but we're excited with the drug. We think it'll really help patients.

Michael Schmidt Analyst — Guggenheim

And then XUS, would you anticipate launching yourself or would you partner the drug XUS?

Well, that's a really good question. The very first drug at CGen, I did partner, it was at Cetris, and I partnered that with Takeda. And Takeda did a great job, and that drug became, a couple years ago, I remember, U.S. was $1.2 billion, and international, Takeda's thing, was $1 billion. So it was a $2.2 billion drug. So it certainly was good. And you look back at CGen and that deal with the first drug, it brought in hundreds of millions of dollars up front, hundreds of millions in milestones, and very strong royalties. And it enabled CGen to plow the money into other drugs. It became a $40 billion company. So it's not a bad, you know, way to go is to have, for your first drug, a partnership outside the U.S. I will tell you that there's certainly interest in varagastat in many different ways. But, you know, I also have a lot of experience launching drugs. So, you know, my default position is keeping the drug and keeping our ADCs. There's a lot of interest in our ADCs as well and not selling off assets yet. That's the default position. Of course, if there's really very productive deals, we'll look at it and think about it. But it's not something we're going out pounding the pavement saying, we have to do this or else we won't survive.

Michael Schmidt Analyst — Guggenheim

Okay. So maybe then shifting over to your ADC pipeline. So, you know, first question, there are a lot of other ADC product candidates now being pursued by industry. You were obviously one of the original innovators in this space, but how do you construct your ADC portfolio? What is the concept behind, you know, target selection and then also payload technology that you're using at Immunome?

So with ADCs, 30 years ago, I started working in ADCs, and at the time, there was only natural product drugs. And so I wanted to solve a problem to make it much simpler to use, so I started to use synthetic drugs. And CGEN was the first company to use synthetic drugs. Then you can make a drug linker unit that you manufacture, and a conjugate was two pieces. And in the past, it was three pieces. And it was much easier, and we used enzyme-cleavable linkers. It was much safer and really ushered in the modern ADC. And so now, what's the issue? So I looked at the field, and when we put together, you know, the Immunome Company, as it's known today, and said, what's wrong with ADCs? Well, first of all, the two largest types of ADCs came from the CGen, now Pfizer, ADC components and the Daiichi ADC components. And those are those two structures, if you will, have been used more than any other structure in ADC world. And in fact, a lot of what people are doing now are just tweaks of those. And but both of them are susceptible to resistance. So that's something I wanted to, it always bothered me. So we now have a payload that's outside of all the resistant mechanisms that we can test for. So that's a big advantage. Something else that's really important is permeability. And when you look at ADCs, you want something, you know, your drug, your drug, because you're bringing, the antibodies bring it to a receptor, you're getting inside the cell, and then you want your small molecule to be permeable. And the reason why you want your payload to be permeable is due to something called bystander activity. Now, I've been treating mice with tumors for decades, and you use a human cell line, and you have a homogeneous tumor. And I've been treating humans with tumors for decades, and they all have heterogeneous tumors, so it doesn't really match. So what you need in a human, because they're heterogeneous, is you need to have the ability to, once it gets into a cell, you need it to also impact cells around it. And that's where permeability comes in. So we have our payload not only is outside of resistance, but it's very permeable. So that's two advantages, and I can sit here talking for the next 20 minutes about all the other advantages we have, but I also want to talk about the antibody, because you asked about that. On the antibody, what's really important is to go after targets that have high expression in tumors and very low or minimal expression in normal tissues. Since most tumor antigens emerged from normal antigens, it's really hard to find an antigen for tumors that has zero on normal cells. But what you try to do is try to find the minimum amount and not on tissues, you know, like retina or things like that. So you try to find, you know, as best of the therapeutic window as you can. Again, one of the things we do, which is really important, is we look for rapid internalization of an antibody. So a lot of companies that work with ADCs, they pick an antibody, and they have it, and they just identify an antibody, and they say, okay, we're going to use this to target X. We don't do it that way. We screen thousands and thousands of antibodies looking for the best internalizers. And what makes that important is that when an antibody binds to the receptor, it's really not binding to the receptor. That's too generic. It's binding to an epitope within the receptor. A receptor is like a big cup, and the epitopes are dots within the cup. That's actually what an antibody is binding to. So you could have an antibody binding to an epitope, and it does not internalize. Or you can have antibody binding to an epitope and it internalizes rapidly. Some of them signal, some of them don't signal. That's why, for, you know, for years, people look at certain targets, they say, oh, well, that doesn't internalize or that doesn't signal. Not necessarily true. You have to find different epitopes. So we are very professional and experienced at looking and selecting antibodies. Our head of antibody technologies came from CGen and has a long history of picking out antibodies. So we've gone after some very exciting targets. And the other thing we're not doing with targets is we're not going after and becoming the 25th HER2, Trope 2, Nectin 4, you know, the ones that are out there. I don't fully understand why there are dozens of lookalike ADCs in development. It's really, really hard to take some of these ADCs and supplant them. And the trial size would have to be huge. And the years are huge. So instead, what we're doing is we're going after some very novel, exciting new targets. The first one is for heme, you know, lymphomas. But the next seven are all for solid tumors. And we have now, I think it's five drugs in clinical development right now. So we, and there's more INDs coming. So we're really cranking forward hard. You know, I would like to say that every one of our drugs is going to be a commercial success. It's never the case. My hit rate in my career has been very high compared to industry average. I think it will continue that way, but I also think that having multiple drugs that you're developing with great science is the way to win.

Michael Schmidt Analyst — Guggenheim

Yeah, great. So maybe diving into some of those a little deeper, a question on IM1021, which is your ROAR 1 ADC. The first one, really, to have clinical data disclosures this year at ASH. We saw the abstracts recently. So, yeah, what does the early data tell you about IM-1021, and has it met your own bar to, you know, go into next steps?

So, certainly, IM-1021, which targets ROR1, that is in trials, and it's in, you know, expanded trials. So, we're certainly investing in it, and we're doing a lot of work in it in lymphoma. You know, when you start working with an ADC, It's a little, it's complicated, and you have to be a little picky when you work with this, and I have developed and gotten approved as many ADCs as anybody in the world, as you know, and so you have to start out and you have to know what the dose and schedule are. It's really important. And I'll give you just a quick little background story. Etcetris used weekly. It was very active, but had overlapping toxicity due to long half-life. So the short story is that Cetras going to every third week... It became a $2 billion drug because it didn't have overlapping heme tox and was very effective. So weakly, effective, but too toxic. So every ADC has a very steep curve for response versus toxicity. Because ADCs are potent directed antibodies. So these are not drugs that have gigantic therapeutic windows. They just don't. Nobody's do. Whether it's NHER2 or any of the ones I made, they have pretty narrow therapeutic windows. And for drug developers like me, it's to find that therapeutic window. So you look at Etcetra, and the next drug, PADCEF, we said, okay, let's start it. I'm so smart. We're going to start it every third week, just like Etcetra. Well, that was wrong, too, because the half-life was short. So Etcetra, so PADCEF, which started every third week, which was safe but not that effective, goes to weekly, and now it's a $3 billion drug. So what you see is you have to first identify the dose and schedule. So now let's take this to 1021. The very first in human data come out. And we started it every third week and we go out into the world and we have, you know, a lot of responses. I think we reported of what we treated 53% in the abstract responses. Keep in mind that our abstract was a data cut from June. It feels like a million years ago, you know, it's a data cut from June. You have to get the data and everything to put an abstract in by the beginning of August. So You know, at the conference, we're going to show a lot more data than what was in the data cut, and, you know, I don't know exactly, but it could be double the number of patients, something like that. I don't know. And, in fact, the data cut for what's going to be presented at ASHE was probably October. So we continue to treat patients, you know, and, you know, just because there's a conference doesn't mean you're stopping or anything. We're, you know, we have a program, and the most important thing is to collect the data and work with FDA and work with doctors and patients. So I think what we have is a very active drug, and when you look at We're going to get lymphoma in third line plus, which is what we're doing. Patients have had a rituxin chemoregimen. Patients have had CAR-T, T-cell engagers. I mean, these are heavily pretreated patients. Once they're in third line plus, there's not really good choices. There's a bunch of different choices that will give you 20% to 30% response rate. A lot of them have toxicity. So what we need to do is not come up with another drug that has 28% response rate. That, to me, would be something we would announce that we're closing the program. What we need is something differentiated, and we need 50%, 60%, 70% response rate. We need outpatient therapy because, as you know, a lot of the T-cell engagers, you have to go into the hospital to get them. Because of, you know, CLS or CRS, whatever you want to call it. And so we want outpatient therapy. We want it to be a ubiquitous drug for B-cell lymphoma so that you don't even have to screen for it. And we want something that has a differentiated response rate of 50%, 60%, 70% so that in third line plus, it will be drug of choice. And you could go and quickly get an approval in third line plus, which is exactly what I did with Etcetras first. Then I moved that into earlier lines. And when you have a really good outpatient drug with a differentiated response rate, doctors are very excited about bringing it early and combining it with drugs. And so that's the way to make this into an initial approval, into a much bigger market opportunity and help patients. So we're cranking along. Our first report on this shows, you know, if you look at all doses and everything we looked at, you know, over 50 percent response rate. But what's not in there is saying, well, what's the right dose and schedule? And could we take what we learned from our initial studies and improve it? And can we go to 53% and make that our bottom line? And what can we do to get up to 60%, 70%? And how do you do that? And so that's what we are working on now. And so there'll be more presented at the conference, and we are still working really hard on it. So I'm excited with 1021, the Rural One drug. I'm not here yet saying we're ready to get it approved tomorrow, but we're, you know, I don't like wasting money and time on drugs, and so I'm still very excited about it.

Michael Schmidt Analyst — Guggenheim

How close to finding an RP2D are you at this point?

You know, that's something that we're going to be presenting data at the conference. I don't feel comfortable talking about, you know, whether we've, you know, fully selected our recommended phase two dose yet or not. But, you know, it's coming in a few weeks as ash, three or four weeks. And we'll present a lot more data and we'll continue to crank forward. So that's something keenly in our in our in our mind. I mean, one of the goals here is to try to do a single arm, single agent approval pathway in third line plus. That's exactly how Etcetris and Padset were approved, for instance, but you have to do that based on differentiated activity in a disease setting that's late-line and there's not a lot of really good alternatives. But to do that, to get the FDA to say, yeah, that's something we'll review. You need to bring forward differentiated data. You can't bring forward something that's the same as everyone else. And they'll say, no, you'll have to do a big, giant, randomized study and all that. And so that's our goal, is to get differentiated data, outpatient therapy to really help patients.

Michael Schmidt Analyst — Guggenheim

In your opinion, what is the efficacy bar for an accelerated approval these days in late-line, DLBCL, and how important are CRs as opposed to ORR?

Yeah. So first of all, I don't know. There's not like a written document from FDA saying, here's the bar. I would say it's... And it's complicated when you look at it. The CRs is you need to have some CR rate. It's not 100%, but you need to have some 20%, 30% CRs, in my opinion, not in pancreatic cancer like you just heard from RevMed, but in lymphoma, you need to have some CRs. And I don't know the exact rate. Like if you look at a waterfall plot and you have a 50% response rate, but every single patient is below the line. And so you have 50% having reducing disease and 50% having a response rate. That means 100% of the patients have tumor shrinkage. That's a good 50% response rate. Or you could have a 60% response rate and the other 40 is above the line and they're growing. That's not a very good 60% response rate, is it? So having a set number is not really, in my experience, of decades with the FDA. They look at the whole data. They look at the data set and say, what happens to the patients that respond? How long is the duration? What about the patients that don't respond? Are their tumors shrinking? How long is that duration? Is this safe for outpatient therapy? And you have to have all of the pieces and not just what is your response rate and not see the rest because duration and other parts of this are very important.

Michael Schmidt Analyst — Guggenheim

Great. So we didn't get to talk about the rest of the pipeline. Let me ask you one before we wrap up. How important is this ASH-ROR1 data in terms of validating the rest of the pipeline?

You know, I mean, I think every piece of data is important. You know, some folks have said, gee, if your data in lymphoma is really good, that means your solid tumors will work. And some people say, well, if it's not good, then your solid tumors won't work. I think that's a little bit overreaching.

Michael Schmidt Analyst — Guggenheim

Okay, great. Well, let's wrap up here, but looking forward to Ash, then, for these important updates, and looking forward to talking to you then. Thank you, Clay. Appreciate it. Wow.

Analyst Q&A · 1 question
Full-screen source Call document